Novo Nordisk stock slips 7.5% this year as Q2 outlook improves
Published on 08/22/2026 at 06:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk A/S (DK0062498333) stock closed at DKK 300.85 on August 21, 2026, and the share price was still 7.50% lower for 2026 despite a 1.59% gain in the latest session.
The latest company transcript was the H1 2026 earnings call on August 5, 2026, and the press-release trail now includes a share repurchase programme from August 17, 2026, plus the August 10, 2026 partnership with AWS on drug discovery through AI.
Q2 2026 still sets the tone
Management reported adjusted operating profit of DKK 33,389 million for Q2 2026 and raised the 2026 outlook, while the market still values the company at DKK 1,331 billion. The stock also trades at 13.7 times 2026 earnings, which leaves the rerating story tied to follow-through rather than one quarter alone.
That matters because the year-to-date move is still negative even after the guidance lift. By contrast, the 1-week gain was 2.09%, showing that the market has started to rebuild some confidence without reversing the full-year damage.
Competition stays in the frame
Recent coverage has kept Novo Nordisk in the same conversation as obesity-drug rivals, and the latest analyst flow has leaned more cautious, with one August 12 note cutting the shares to Hold and trimming the target to $47. The broader context is a market that now prices in execution, pricing discipline, and pipeline clarity at the same time.
The company profile still matters here: diabetes and obesity treatments account for 93.7% of sales, so every change in GLP-1 demand or pricing pressure carries outsize weight. For investors, that concentration explains why a single earnings release can move the stock less than the follow-through on guidance and competitive positioning.
Wegovy remains the key product
Wegovy is Novo Nordisk's flagship obesity treatment and the product most closely tied to the company's growth debate. The latest news flow around lower-dose Wegovy tablets shows how much attention still sits on the next stage of the franchise rather than on the legacy diabetes base alone.
Shares keep a close range
As of August 21, 2026, Novo Nordisk traded in a 1-month range of DKK 285.8 to DKK 338.7 and a 1-year range of DKK 224.25 to DKK 409.95. The quote screen also shows a free-float of 71.32% and an average target price of DKK 309.73, which keeps the current price close to the consensus anchor.
Company details
Company: Novo Nordisk A/S
ISIN: DK0062498333
Ticker: NOVO B
Exchange: Nasdaq Copenhagen
Price (as of August 21, 2026, 11:20 a.m. ET): DKK 300.85
Market cap: DKK 1,331 billion
Sector / Industry: Pharmaceuticals
Index membership: OMX Copenhagen 25
Next earnings date: November 3, 2026
